ARKUDA THERAPEUTICS
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
ARKUDA THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.arkudatx.com
Total Employee:
11+
Status:
Active
Contact:
857-201-2789
Total Funding:
108 M USD
Technology used in webpage:
Euro Google Google Cloud
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Appili Therapeutics
Appili Therapeutics is an anti-infective pharmaceutical development company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Theseus Pharmaceuticals
Theseus Pharmaceuticals is a technology-based company.
Transcode Therapeutics
TransCode Therapeutics is a pre-clinical biopharmaceutical company.
Zomedica
Zomedica is a veterinary pharmaceutical company.
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
Johannes Fruehauf Investor, Board Member @ Arkuda Therapeutics
Investor, Board Member
2019-01-01
Gerhard Koenig Founder & CEO @ Arkuda Therapeutics
Founder & CEO
Duane Burnett Co-Founder and Chief Technology Officer @ Arkuda Therapeutics
Co-Founder and Chief Technology Officer
2023-01-01
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Arkuda Therapeutics
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Arkuda Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Arkuda Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Arkuda Therapeutics
Eli Lilly
Eli Lilly investment in Series B - Arkuda Therapeutics
Mission BioCapital
Mission BioCapital investment in Series B - Arkuda Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series B - Arkuda Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Arkuda Therapeutics
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Arkuda Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Arkuda Therapeutics
Official Site Inspections
http://www.arkudatx.com Semrush global rank: 3.84 M Semrush visits lastest month: 3.06 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arkuda Therapeutics"
Arkuda: Changing the Trajectory of Neurodegenerative …
Discovering therapies that bring new hope to those affected by frontotemporal dementia and other neurodegenerative diseases.See details»
Arkuda Therapeutics - Crunchbase Company Profile
Contact Email info@arkudatx.com Phone Number 857-201-2789 Arkuda Therapeutics is a biotechnology company leveraging new insights into …See details»
Arkuda JNJ PR Draft Jan 6 edits[75] vFINAL.docx - Google Docs
Its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.) and Eli ... To learn more visit w w w.arkudatx.com . Media Contact: Amanda Sellers Deerfield Group …See details»
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Jan 9, 2025 Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission BioCapital, Johnson & Johnson (through its …See details»
Arkuda Therapeutics - 2025 Company Profile - Tracxn
Mar 25, 2025 Arkuda Therapeutics - Developer of therapeutic solutions for neurological disorders. Raised a total funding of $108M over 2 rounds from 8 investors. Founded by Duane …See details»
Arkuda Therapeutics Company Overview, Contact Details
Feb 10, 2022 Arkudatx hired Duane Burnett as Chief Technology Officer on Apr 4th '23. Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of …See details»
Arkuda Therapeutics Overview | SignalHire Company Profile
Arkuda Therapeutics is a private company that has been in the industry for 31 years. The company currently specializes in the Biotechnology, Life Sciences, Pharmaceuticals areas. …See details»
Arkuda Therapeutics - Overview, News & Similar companies
Jul 18, 2023 Arkuda Therapeutics contact info: Phone number: (617) 579-1306 Website: www.arkudatx.com What does Arkuda Therapeutics do? Arkuda Therapeutics is a …See details»
Arkuda Therapeutics - Craft
Arkuda Therapeutics is a biotechnology company developing medicines to change the trajectory of neurodegenerative disease. Its lead compounds aim to correct progranulin deficiency and …See details»
Arkuda Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Apr 1, 2025 www.arkudatx.com. Startups | Holding Company | 2018 | Massachusetts, United States | 10-50 | www.arkudatx.com. Last update 01 Apr 2025. Overview. Pipeline. Deal. …See details»
Arkuda Therapeutics - PitchBook
Arkuda Therapeutics General Information Description. Developer of neurodegenerative medicines designed to change the trajectory of neurodegenerative disease. The company's medicines leverage new insights into progranulin and lysosomal biology, enabling healthcare providers to improve the health of cells in the brain, delay disease progression, and even the onset of …See details»
Arkuda Therapeutics - LinkedIn
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.See details»
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Jan 9, 2025 * On February 27, 2024 Arkuda announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.. …See details»
Arkuda Therapeutics - workinbiotech.com
Arkuda Therapeutics is developing therapies for neurodegenerative diseases by targeting the root cause. Novel understanding of the cause of neurodegenerative diseases is attributed to …See details»
Arkuda Therapeutics Announces Option Exercise and Asset Purchase
Jan 9, 2025 Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, abrdn plc, Mission BioCapital, Johnson & Johnson (through its …See details»
Arkuda - VentureRadar
Website: http://www.arkudatx.com/ Develops medicines targeting progranulin deficiency and lysosomal dysfunction in frontotemporal dementia, leveraging insights in ...See details»
John Ross, MS, RLATG, DSP, DABT - Arkuda Therapeutics
John provides nonclinical safety leadership to guide drug discovery and development programs at Arkuda. He is passionate about contributing to a team developing treatments for some of the …See details»
Gerhard Koenig, PHD - Arkuda Therapeutics
Gerhard is a senior R&D biotech leader with over 30 years of experience spanning drug discovery through Phase 3 development. He founded Arkuda Therapeutics in early 2018 to develop therapeutics for serious neurological diseases. As President & CEO, he raised more than $110 million in Series A (Atlas Venture, Pfizer Venture, and Tekla) and Series […]See details»
Arkuda Therapeutics Company Profile | Management and
Www.arkudatx.com . Arkuda Therapeutics Profile and History. Arkuda Therapeutics is a biotechnology company applying new insights into lysosomal biology to drive the development …See details»
Arkuda Therapeutics, Inc. (Arkuda Therapeutics, Inc.) - 药物管线_专 …
Recent research has revealed the potential of lipidomics and metabolomics in identifying new biomarkers and mechanistic insights for neurodegenerative disorders.To contribute to this …See details»